Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies

References

• Bjornsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–334. DOI:10.1007/s00204-015-1456-2
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Tolosa L, Donato MT. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol. 2016;36(6):752–768. DOI:10.1002/jat.3277
   PubMed Web of Science ®Google Scholar
• Lewis DF, Ioannides C, Parke DV. Cytochromes p450 and species differences in xenobiotic metabolism and activation of carcinogen. Environ Health Perspect. 1998;106(10):633–641.
   PubMed Web of Science ®Google Scholar
• Park BK, Laverty H, Srivastava A, et al. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem Biol Interact. 2011;192(1–2):30–36. DOI:10.1016/j.cbi.2010.09.011
   PubMed Web of Science ®Google Scholar
• Donato MT, Jover R, Gomez-Lechon MJ. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab. 2013;14(9):946–968.
   PubMed Web of Science ®Google Scholar
• Godoy P, Hewitt NJ, Albrecht U, et al. Recent advances in 2d and 3d in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and adme. Arch Toxicol. 2013;87(8):1315–1530. DOI:10.1007/s00204-013-1078-5
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Tolosa L, Conde I, et al. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol. 2014;10(11):1553–1568. DOI:10.1517/17425255.2014.967680
   PubMed Web of Science ®Google Scholar
• Xu JJ, Diaz D, O’Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact. 2004;150(1):115–128. DOI:10.1016/j.cbi.2004.09.011
   PubMed Web of Science ®Google Scholar
• Abraham VC, Towne DL, Waring JF, et al. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J Biomol Screen. 2008;13(6):527–537. DOI:10.1177/1087057108318428
   PubMed Web of Science ®Google Scholar
• Tolosa L, Gomez-Lechon MJ, Donato MT. High-content screening technology for studying drug-induced hepatotoxicity in cell models. Arch Toxicol. 2015;89(7):1007–1022. DOI:10.1007/s00204-015-1503-z.
   PubMed Web of Science ®Google Scholar
• van Vliet E, Daneshian M, Beilmann M, et al. Current approaches and future role of high content imaging in safety sciences and drug discovery. Altex. 2014;31(4):479–493. DOI:10.14573/altex.1405271
   PubMedGoogle Scholar
• Persson M, Loye AF, Jacquet M, et al. High-content analysis/screening for predictive toxicology: application to hepatotoxicity and genotoxicity. Basic Clin Pharmacol Toxicol. 2014;115(1):18–23. DOI:10.1111/bcpt.12200
   PubMed Web of Science ®Google Scholar
• Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol. 2010;28(5):237–245. DOI:10.1016/j.tibtech.2010.02.005
   PubMed Web of Science ®Google Scholar
• Kim JA, Han E, Eun CJ, et al. Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity. Toxicol Lett. 2012;214(2):175–181. DOI:10.1016/j.toxlet.2012.08.027
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Irwin W, Diaz D, et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol. 2006;80(9):580–604. DOI:10.1007/s00204-006-0091-3.
   PubMed Web of Science ®Google Scholar
• Tolosa L, Pinto S, Donato MT, et al. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol Sci. 2012;127(1):187–198. DOI:10.1093/toxsci/kfs083
   PubMed Web of Science ®Google Scholar
• Leist M, Lidbury BA, Yang C, et al. Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. Altex. 2012;29(4):373–388.
   PubMedGoogle Scholar
• Foldes G, Mioulane M. High-content imaging and analysis of pluripotent stem cell-derived cardiomyocytes. Methods Mol Biol. 2013;1052:29–39. DOI:10.1007/7651_2013_25
   PubMedGoogle Scholar
• Buchser W, Collins M, Garyantes T, et al. Assay development guidelines for image-based high content screening, high content analysis and high content imaging. In: Sittampalam GS, Coussens NP, Nelson H, et al. editors. Assay guidance manual. Bethesda (MD):Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.
   Google Scholar
• Inglese J, Johnson RL, Simeonov A, et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol. 2007;3(8):466–479. DOI:10.1038/nchembio.2007.17
   PubMed Web of Science ®Google Scholar
• Tsiper MV, Sturgis J, Avramova LV, et al. Differential mitochondrial toxicity screening and multi-parametric data analysis. Plos One. 2012;7(10):e45226. DOI:10.1371/journal.pone.0045226
   Google Scholar
• van de Water FM, Havinga J, Ravesloot WT, et al. High content screening analysis of phospholipidosis: validation of a 96-well assay with cho-k1 and hepg2 cells for the prediction of in vivo based phospholipidosis. Toxicol In Vitro. 2011;25(8):1870–1882. DOI:10.1016/j.tiv.2011.05.026.
   PubMed Web of Science ®Google Scholar
• Westerink WM, Schirris TJ, Horbach GJ, et al. Development and validation of a high-content screening in vitro micronucleus assay in cho-k1 and hepg2 cells. Mutat Res. 2011;724(1–2):7–21. DOI:10.1016/j.mrgentox.2011.05.007
   PubMed Web of Science ®Google Scholar
• Xu JJ, Henstock PV, Dunn MC, et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci. 2008;105(1):97–105. DOI:10.1093/toxsci/kfn109.
   PubMed Web of Science ®Google Scholar
• Dykens JA, Jamieson JD, Marroquin LD, et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci. 2008;103(2):335–345. DOI:10.1093/toxsci/kfn056
   PubMed Web of Science ®Google Scholar
• Tolosa L, Carmona A, Castell JV, et al. High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins. Arch Toxicol. 2015;89(10):1847–1860. DOI:10.1007/s00204-014-1334-3
   PubMed Web of Science ®Google Scholar
• Tolosa L, Gomez-Lechon MJ, Perez-Cataldo G, et al. Hepg2 cells simultaneously expressing five p450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved. Arch Toxicol. 2013;87(6):1115–1127. DOI:10.1007/s00204-013-1012-x
   PubMed Web of Science ®Google Scholar
• Cosgrove BD, King BM, Hasan MA, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol. 2009;237(3):317–330. DOI:10.1016/j.taap.2009.04.002
   PubMed Web of Science ®Google Scholar
• Pernelle K, Le Guevel R, Glaise D, et al. Automated detection of hepatotoxic compounds in human hepatocytes using heparg cells and image-based analysis of mitochondrial dysfunction with jc-1 dye. Toxicol Appl Pharmacol. 2011;254(3):256–266. DOI:10.1016/j.taap.2011.04.018
   PubMed Web of Science ®Google Scholar
• Apostolova N, Gomez-Sucerquia LJ, Moran A, et al. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol. 2010;160(8):2069–2084. DOI:10.1111/j.1476-5381.2010.00866.x
   PubMed Web of Science ®Google Scholar
• Persson M, Loye AF, Mow T, et al. A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods. 2013;68(3):302–313. DOI:10.1016/j.vascn.2013.08.001
   PubMed Web of Science ®Google Scholar
• Ye N, Qin J, Shi W, et al. Cell-based high content screening using an integrated microfluidic device. Lab Chip. 2007;7(12):1696–1704. DOI:10.1039/b711513j
   PubMed Web of Science ®Google Scholar
• Donato MT, Tolosa L, Jimenez N, et al. High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay. J Biomol Screen. 2012;17(3):394–400. DOI:10.1177/1087057111427586
   PubMed Web of Science ®Google Scholar
• Fujimura H, Murakami N, Kurabe M, et al. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J Appl Toxicol. 2009;29(4):356–363. DOI:10.1002/jat.1420
   PubMed Web of Science ®Google Scholar
• Pradip A, Steel D, Jacobsson S, et al. High content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis. Stem Cells Int. 2016;2016:2475631. DOI:10.1155/2016/1243659
   PubMed Web of Science ®Google Scholar
• Wink S, Hiemstra S, Herpers B, et al. High-content imaging-based bac-gfp toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2016. DOI:10.1007/s00204-016-1781-0
   Google Scholar
• Wink S, Hiemstra S, Huppelschoten S, et al. Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment. Chem Res Toxicol. 2014;27(3):338–355. DOI:10.1021/tx4004038
   PubMed Web of Science ®Google Scholar
• Shariff A, Kangas J, Coelho LP, et al. Automated image analysis for high-content screening and analysis. J Biomol Screen. 2010;15(7):726–734. DOI:10.1177/1087057110370894
   PubMed Web of Science ®Google Scholar
• Chen M, Tung CW, Shi Q, et al. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model. Arch Toxicol. 2014;88(7):1439–1449. DOI:10.1007/s00204-014-1276-9
   PubMed Web of Science ®Google Scholar
• Giuliano KA, Haskins JR, Taylor DL. Advances in high content screening for drug discovery. Assay Drug Dev Technol. 2003;1(4):565–577. DOI:10.1089/154065803322302826
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Donato MT, Castell JV, et al. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab. 2004;5(5):443–462.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, O’Connor JE, Lahoz A, et al. Identification of apoptotic drugs: multiparametric evaluation in cultured hepatocytes. Curr Med Chem. 2008;15(20):2071–2085.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechon MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev. 2007;39(1):159–234. DOI:10.1080/03602530601093489
   PubMed Web of Science ®Google Scholar
• De Bruyn T, Sempels W, Snoeys J, et al. Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition. J Pharm Sci. 2014;103(6):1872–1881. DOI:10.1002/jps.23933
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Castell JV, et al. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab. 2008;9(1):1–11.
   PubMed Web of Science ®Google Scholar
• Guo L, Dial S, Shi L, et al. Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos. 2011;39(3):528–538. DOI:10.1124/dmd.110.035873
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Tolosa L. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening. Arch Toxicol. 2016;90(9):2049–2061. DOI:10.1007/s00204-016-1756-1
   PubMed Web of Science ®Google Scholar
• Yi F, Liu GH, Izpisua Belmonte JC. Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein Cell. 2012;3(4):246–250. DOI:10.1007/s13238-012-2918-4
   PubMed Web of Science ®Google Scholar
• Katsuda T, Sakai Y, Ochiya T. Induced pluripotent stem cell-derived hepatocytes as an alternative to human adult hepatocytes. J Stem Cells. 2012;7(1):1–17.
   PubMedGoogle Scholar
• Medine CN, Lucendo-Villarin B, Storck C, et al. Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med. 2013;2(7):505–509. DOI:10.5966/sctm.2012-0138
   PubMed Web of Science ®Google Scholar
• Grimm FA, Iwata Y, Sirenko O, et al. High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes. Assay Drug Dev Technol. 2015;13(9):529–546. DOI:10.1089/adt.2015.659
   PubMed Web of Science ®Google Scholar
• Dragovic S, Vermeulen NP, Gerets HH, et al. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Arch Toxicol. 2016;90:2979–3003. DOI:10.1007/s00204-016-1845-1.
   PubMed Web of Science ®Google Scholar
• Abraham VC, Taylor DL, Haskins JR. High content screening applied to large-scale cell biology. Trends Biotechnol. 2004;22(1):15–22. DOI:10.1016/j.tibtech.2003.10.012
   PubMed Web of Science ®Google Scholar
• Shahane SA, Huang R, Gerhold D, et al. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. J Biomol Screen. 2014;19(1):66–76. DOI:10.1177/1087057113502851
   PubMed Web of Science ®Google Scholar
• Garside H, Marcoe KF, Chesnut-Speelman J, et al. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of hepg2 cells and cryopreserved primary human hepatocytes. Toxicol In Vitro. 2014;28(2):171–181. DOI:10.1016/j.tiv.2013.10.015
   PubMed Web of Science ®Google Scholar
• Saito J, Okamura A, Takeuchi K, et al. High content analysis assay for prediction of human hepatotoxicity in heparg and hepg2 cells. Toxicol In Vitro. 2016;33:63–70. DOI:10.1016/j.tiv.2016.02.019
   PubMed Web of Science ®Google Scholar
• Schurdak ME, Vernetti LA, Abel SJ, et al. Adaptation of an in vitro phospholipidosis assay to an automated image analysis system. Toxicol Mech Methods. 2007;17(2):77–86. DOI:10.1080/15376510600860185
   PubMed Web of Science ®Google Scholar
• Feng B, Xu JJ, Bi YA, et al. Role of hepatic transporters in the disposition and hepatotoxicity of a her2 tyrosine kinase inhibitor cp-724,714. Toxicol Sci. 2009;108(2):492–500. DOI:10.1093/toxsci/kfp033
   PubMed Web of Science ®Google Scholar
• Xu JJ, Dunn MC, Smith AR, et al. Assessment of hepatotoxicity potential of drug candidate molecules including kinase inhibitors by hepatocyte imaging assay technology and bile flux imaging assay technology. Methods Mol Biol. 2012;795:83–107. DOI:10.1007/978-1-61779-337-0_6
   PubMedGoogle Scholar
• Germano D, Uteng M, Pognan F, et al. Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment. Toxicol In Vitro. 2015;30(1 Pt A):79–94. DOI:10.1016/j.tiv.2014.05.009
   PubMed Web of Science ®Google Scholar
• Tolosa L, Gomez-Lechon MJ, Lopez S, et al. Human upcyte hepatocytes: characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing. Toxicol Sci. 2016;152(1):214–229. DOI:10.1093/toxsci/kfw078
   PubMed Web of Science ®Google Scholar
• Tolosa L, Gomez-Lechon MJ, Jimenez N, et al. Advantageous use of heparg cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016;302:1–9. DOI:10.1016/j.taap.2016.04.007
   PubMed Web of Science ®Google Scholar
• Sirenko O, Hesley J, Rusyn I, et al. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev Technol. 2014;12(1):43–54. DOI:10.1089/adt.2013.520.
   PubMed Web of Science ®Google Scholar
• Ranade AR, Wilson MS, McClanahan AM, et al. High content imaging and analysis enable quantitative in situ assessment of cyp3a4 using cryopreserved differentiated heparg cells. J Toxicol. 2014;2014:291054. DOI:10.1155/2014/291054
   PubMedGoogle Scholar
• McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol. 2006;16(14):R551–R560. DOI:10.1016/j.cub.2006.06.054
   PubMed Web of Science ®Google Scholar
• Tait SW, Green DR. Mitochondria and cell signalling. J Cell Sci. 2012;125(Pt 4):807–815. DOI:10.1242/jcs.099234
   PubMed Web of Science ®Google Scholar
• Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54(4):773–794. DOI:10.1016/j.jhep.2010.11.006
   PubMed Web of Science ®Google Scholar
• Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44(1):34–87. DOI:10.3109/03602532.2011.604086
   PubMed Web of Science ®Google Scholar
• Wewering F, Jouy F, Wissenbach DK, et al. Characterization of chemical-induced sterile inflammation in vitro: application of the model compound ketoconazole in a human hepatic co-culture system. Arch Toxicol. 2016. DOI:10.1007/s00204-016-1686-y
   PubMedGoogle Scholar
• Tolosa L, Donato MT, Perez-Cataldo G, et al. Upgrading cytochrome p450 activity in hepg2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment. Toxicol In Vitro. 2012;26(8):1272–1277. DOI:10.1016/j.tiv.2011.11.008
   PubMed Web of Science ®Google Scholar
• Fogel AI, Martin SE, Hasson SA. Application of imaging-based assays in microplate formats for high-content screening. Methods Mol Biol. 2016;1439:273–304. DOI:10.1007/978-1-61779-337-0_6
   PubMedGoogle Scholar
• Fraietta I, Gasparri F. The development of high-content screening (hcs) technology and its importance to drug discovery. Expert Opin Drug Discov. 2016;11(5):501–514. DOI:10.1517/17460441.2016.1165203.
   PubMed Web of Science ®Google Scholar
• Zock JM. Applications of high content screening in life science research. Comb Chem High Throughput Screen. 2009;12(9):870–876.
   PubMed Web of Science ®Google Scholar
• O’Brien PJ. High-content analysis in toxicology: screening substances for human toxicity potential, elucidating subcellular mechanisms and in vivo use as translational safety biomarkers. Basic Clin Pharmacol Toxicol. 2014;115(1):4–17. DOI:10.1111/bcpt.12227
   PubMed Web of Science ®Google Scholar
• Bale SS, Vernetti L, Senutovitch N, et al. In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood). 2014;239(9):1180–1191. DOI:10.1177/1535370214531872
   PubMed Web of Science ®Google Scholar
• Cyprotex. [cited 2016 Nov 08]. Available from: www.cyprotex.com
   Google Scholar
• HCS Pharma. [cited 2016 Nov 09]. Available from: hcs-pharma.com
   Google Scholar
• Evotec. [cited 2016 Nov 08]. Available from: www.evotec.com
   Google Scholar
• Fluofarma. [cited 2016 Nov 14] Available from: www.fluofarma.com/
   Google Scholar
• Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772. DOI:10.1038/nbt.2989
   PubMed Web of Science ®Google Scholar
• Bhise NS, Ribas J, Manoharan V, et al. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release. 2014;190:82–93. DOI:10.1016/j.jconrel.2014.05.004
   PubMed Web of Science ®Google Scholar
• Ma C, Zhao L, Zhou EM, et al. On-chip construction of liver lobule-like microtissue and its application for adverse drug reaction assay. Anal Chem. 2016;88(3):1719–1727. DOI:10.1021/acs.analchem.5b03869
   PubMed Web of Science ®Google Scholar